A5067129820- Breast Cancer Treatment Studies
- Economic and Financial Impacts of Cancer
- Advanced Breast Cancer Therapies
- Cancer Risks and Factors
- Health Systems, Economic Evaluations, Quality of Life
- Reproductive Biology and Fertility
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- BRCA gene mutations in cancer
- Innovations in Medical Education
- Cancer Treatment and Pharmacology
- Healthcare cost, quality, practices
- Ovarian function and disorders
- Estrogen and related hormone effects
- Global Cancer Incidence and Screening
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- PARP inhibition in cancer therapy
- Radiomics and Machine Learning in Medical Imaging
- Statistical Methods in Clinical Trials
- Monoclonal and Polyclonal Antibodies Research
- Psychiatric care and mental health services
- Reproductive Health and Contraception
- Biosimilars and Bioanalytical Methods
- Pharmaceutical Economics and Policy
Harvard University
2024-2025
Dana-Farber Cancer Institute
2022-2025
Dana-Farber Brigham Cancer Center
2024-2025
BC Cancer Agency
2020-2021
University of British Columbia
2020
Memorial University of Newfoundland
2018-2019
To provide updated fertility preservation (FP) recommendations for people with cancer. A multidisciplinary Expert Panel convened and the systematic review. One hundred sixty-six studies comprise evidence base. People cancer should be evaluated counseled about reproductive risks at diagnosis during survivorship. Patients interested in or uncertain FP referred to specialists. approaches discussed before cancer-directed therapy. Sperm cryopreservation offered males treatment, testicular sperm...
Although breast cancer is rare and understudied in adults age 40 younger, recent epidemiologic data show an increasing incidence of among young women the United States ongoing inferior long-term outcomes. Given cancers arising at a are more likely to present advanced stages have aggressive biology, multimodal treatments often indicated. Elevated local recurrence risks greater propensity for germline predisposition mutations can impact therapy choices. Recently, escalated systemic regimens...
Abstract Ovarian function suppression (OFS) benefits young women with hormone receptor (HR)-positive breast cancer but they are at risk for ovarian breakthrough. We assessed endocrine effects of gonadotropin-releasing agonist (GnRHa) treatment in a prospective cohort patients aged ≤ 40 years HR-positive cancer. Plasma estradiol (E2), estrone, and follicule-stimulating (FSH) levels were measured from blood samples drawn 1 4 after diagnosis. Patient characteristics, invasive cancer-free...
Background The trial assigning individualized options for treatment (Rx) (TAILORx) confirmed the predictive value of 21‐gene recurrence score (RS) assay in hormone receptor (HR)–positive, HER2‐negative, node‐negative breast cancer and established thresholds chemotherapy benefit younger older patients. Real‐world use RS‐guided costs British Columbia post‐TAILORx were examined. Methods authors assembled 3 cohorts HR‐positive, patients with defined by diagnosis: before RS funding (cohort 1...
Germline pathogenic variants in the BRCA1-associated protein-1 (BAP1) gene cause BAP1 tumor predisposition syndrome (TPDS). TPDS is associated with an increased risk of uveal and cutaneous melanoma, mesothelioma, renal cell carcinoma, several other cancer subtypes. Here, we report a germline nonsense variant (c.850G>T, p.Glu284Ter) patient bladder strong family history malignancy. Concurrently, identified somatic frameshift variant, as expected, immunostaining validated loss protein...
505 Background: Increased TILs are associated with better prognosis in triple-negative BC, including patients (pts) age < 40. However, the role of remains unclear HR+/HER2- BC and little data exist young pts, whom immune microenvironment could be altered by age-related host/tumor differences. We assessed extent composition infiltration HR+ tumors women correlated clinicopathologic features survival outcomes. Methods: From a prospective cohort study diagnosed ≤40, we identified those stage...
Patients with metastatic cancer have a decreased life expectancy, and screening surveillance for new primary cancers, they run the risk of immediate harm little chance any benefit. Choosing Wisely Canada therefore recommends that such investigations be avoided in patients disease.We examined practices subset Newfoundland Labrador. breast seen at provincial clinic during 2014-2016 were identified from Labrador Cancer Registry. For each patient, we assessed whether one or combination...
524 Background: OFS is an important treatment component for premenopausal women with early and advanced HR+ BC optimal efficacy may depend on complete E2 suppression GnRHa, especially when combined aromatase inhibitors (AI). However, standard assays lack sensitivity accuracy at very low concentrations, rendering detection of breakthrough ovarian function challenging. More informative data regarding endocrine effects GnRHa are needed, particularly in young who derive the most benefit from yet...
Implication statement:
 Overuse of healthcare resources is prevalent, including among medical trainees. As front-line clinicians and near-peers, residents are well-positioned to teach resource stewardship students address barriers may face while trying “choose wisely.” We describe the implementation two resident-led, case-based teaching sessions for that focus on stewardship. Similar models can be adapted by at their own institutions enhance proficiency amongst
Abstract Background: Patients with TNBC are highly encouraged to participate in clinical trials given the lack of targeted treatment options for this breast cancer subtype. Yet little is known regarding barriers trial participation population, including impact patients’ understanding about biology. We examined whether disease knowledge and other patient-level factors were associated trials. Methods: From a multicenter, prospective cohort study patients enrolled from 2019-present newly...
e18817 Background: As part of the broader Choosing Wisely Canada campaign, a list was published in May 2015 practices oncology that are commonly performed despite evidence showing negligible benefit and potential to cause harm. One these recommendations is for physicians avoid routine cancer screening or surveillance new primary malignancy patients with metastatic disease. The objective our study assess whether local practice keeping recommendations. Methods: A retrospective review cancers...
382 Background: Using Blood Wisely is a national Choosing Canada (CWC) initiative that challenges hospitals to benchmark themselves on evidence-informed restrictive transfusion strategies, with the aim decrease inappropriate red blood cell (RBC) transfusions in Canada. We previously assessed practices among oncology patients at BC Cancer Vancouver during 12-month period. Here we present results of second audit, after implementation quality improvement (QI) interventions. Methods: RBC records...